Home › Research › Lewy body dementia
Plasma Biomarkers in the Distinction of Alzheimer’s Disease and Frontotemporal Dementia
Estrella Gómez‐Tortosa, Pablo Agüero, Alicia Ruiz-González, Sonia Wagner, Raquel Téllez, Ignacio Mahíllo, Andrea Ruiz-Calvo, María José Sainz et al.. International Journal of Molecular Sciences, 2025-01-30
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Plasma biomarkers are promising tools for the screening and diagnosis of dementia in clinical settings. We analyzed plasma levels of Alzheimer’s core biomarkers, neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP), through single-molecule Array in 108 patients with Alzheimer’s (AD, cerebrospinal fluid with an amyloid+ tau+ neurodegeneration+ profile), 73 patients with frontotemporal dementia (FTD, 24 with genetic diagnosis), and 54 controls. The best area under the curve (AUC) was used to assess the discriminative power. Patients with AD had lower Aß42/40 ratios and NfL levels, along with higher levels of p-tau181 and GFAP, compared with FTD patients. Single biomarkers discriminated well between dementia patients and controls: the Aß42/40 ratio (AUC:0.86) or GFAP (AUC:0.83) was found for AD, and the NfL (AUC:0.84) was found for FTD patients. However, a combination of two (NfL with p-tau181, or the GFAP/NfL ratio, AUCs ~0.87) or three biomarkers (NfL, P-tau181, and Aß42/40 ratio, AUC: 0.90) was required to distinguish between AD and FTD. Biomarker profiles were similar across different FTD phenotypes, except for carriers of PGRN mutations, who had higher levels of NfL than C9orf72 expansion carriers. In our series, NfL alone provided the best distinction between FTD and controls, while a combination of two or three biomarkers was required to obtain good discrimination between AD and FTD.
What this study adds
Evidence grade: Low
The record lists 108 participants. Blood levels of certain proteins differed between people with Alzheimer's disease and frontotemporal dementia, and combining two or three markers was needed to tell the two conditions apart well. Reported effect size: AUC:0.86; AUC:0.83; AUC:0.84.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gómez‐Tortosa, E., Agüero, P., Ruiz-González, A., Wagner, S., Téllez, R., Mahíllo, I., et al. (2025). Plasma Biomarkers in the Distinction of Alzheimer’s Disease and Frontotemporal Dementia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26031231
Vancouver
Gómez‐Tortosa E, Agüero P, Ruiz-González A, Wagner S, Téllez R, Mahíllo I, et al. Plasma Biomarkers in the Distinction of Alzheimer’s Disease and Frontotemporal Dementia. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26031231. PMID: 39940998.
BibTeX
@article{gomeztortosa2025-39940998,
author = {Gómez‐Tortosa, Estrella and Agüero, Pablo and Ruiz-González, Alicia and Wagner, Sonia and Téllez, Raquel and Mahíllo, Ignacio and Ruiz-Calvo, Andrea and Sainz, María José and others},
title = {{Plasma Biomarkers in the Distinction of Alzheimer’s Disease and Frontotemporal Dementia}},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26031231},
pmid = {39940998},
url = {https://doi.org/10.3390/ijms26031231}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Patients with AD had lower Aß42/40 ratios and NfL levels, along with higher levels of p-tau181 and GFAP, compared with FTD patients.
Why it matters
Blood levels of certain proteins differed between people with Alzheimer's disease and frontotemporal dementia, and combining two or three markers was needed to tell the two conditions apart well. This is about improving diagnosis through blood tests, not about treating or curing either disease.
Study details
- Participants108
- Effect sizeAUC:0.86; AUC:0.83; AUC:0.84
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (International Journal of Molecular Sciences) |
| Journal's citation record | 3 / 4 | International Journal of Molecular Sciences: journal h-index 426 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 108 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 4.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Pascual Sánchez‐Juan: h-index 17 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Instituto de Salud Carlos III: institution h-index 649 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39940998) |
| Free to read | 2 / 2 | Free to read |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3390/ijms26031231
- PubMed: 39940998
- Original source →
- Free full text: International Journal of Molecular Sciences →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Related studies in Lewy body dementia from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.